Hasil Pencarian - Luis Paz‐Ares

Perbaiki Hasil
  1. 1
    Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain

    Impact of the COVID-19 outbreak on cancer patient flow and management: experience from a large university hospital in Spain oleh Luis Paz-Ares, Luis Manso, Guillermo De Velasco

    Diterbitkan 2020-05-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  2. 2
    Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects

    Addressing CPI resistance in NSCLC: targeting TAM receptors to modulate the tumor microenvironment and future prospects oleh Solange Peters, Roy S Herbst, Martin Reck, Luis Paz-Ares

    Diterbitkan 2022-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  3. 3
    KRAS oncogene in lung cancer: focus on molecularly driven clinical trials

    KRAS oncogene in lung cancer: focus on molecularly driven clinical trials oleh Emmanuelle Kempf, Benoît Rousseau, Benjamin Besse, Luis Paz-Ares

    Diterbitkan 2016-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  4. 4
    Enhanced Cytotoxic Activity of Mitochondrial Mechanical Effectors in Human Lung Carcinoma H520 Cells: Pharmaceutical Implications for Cancer Therapy

    Enhanced Cytotoxic Activity of Mitochondrial Mechanical Effectors in Human Lung Carcinoma H520 Cells: Pharmaceutical Implications for Cancer Therapy oleh Sergio González Rubio, Sergio González Rubio, Nuria Montero Pastor, Nuria Montero Pastor, Carolina García, Víctor G. Almendro-Vedia, Víctor G. Almendro-Vedia, Irene Ferrer, Irene Ferrer, Paolo Natale, Paolo Natale, Luis Paz-Ares, Luis Paz-Ares, Luis Paz-Ares, Luis Paz-Ares, M. Pilar Lillo, Iván López-Montero, Iván López-Montero

    Diterbitkan 2018-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  5. 5
    Durvalumab in NSCLC: latest evidence and clinical potential

    Durvalumab in NSCLC: latest evidence and clinical potential oleh Nerea Muñoz-Unceta, Isabel Burgueño, Elizabeth Jiménez, Luis Paz-Ares

    Diterbitkan 2018-10-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  6. 6
    Treating -mutant NSCLC: latest evidence and clinical consequences

    Treating -mutant NSCLC: latest evidence and clinical consequences oleh Pilar Garrido, María Eugenia Olmedo, Ana Gómez, Luis Paz Ares, Fernando López-Ríos, Juan Manuel Rosa-Rosa, José Palacios

    Diterbitkan 2017-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  7. 7
    464 2SMALL (NCT04253145) phase I part: lurbinectidine (LUR) in combination with atezolizumab (ATZ) for second line extensive stage small cell lung cancer (ES-SCLC) patients (pts)

    464 2SMALL (NCT04253145) phase I part: lurbinectidine (LUR) in combination with atezolizumab (ATZ) for second line extensive stage small cell lung cancer (ES-SCLC) patients (pts) oleh Luis Paz-Ares, Santiago Ponce Aix, Alejandro Navarro, Reyes Bernabe, Maria Eugenia Olmedo, Trigo Jose Manuel, Jon Zugazagoitia Fraile

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  8. 8
    368 Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors

    368 Consistent pattern of immune activation induced by oncolytic adenovirus ONCOS-102 across diverse types of solid tumors oleh Magnus Jaderberg, Victor Levitsky, Lukasz Kuryk, Sandeep Kumar, Alexander Shoushtari, Anne-Sophie Moller, Luis Paz Ares, Erik Digman Wiklund

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  9. 9
    Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry

    Impact of Heat Shock Protein 90 Inhibition on the Proteomic Profile of Lung Adenocarcinoma as Measured by Two-Dimensional Electrophoresis Coupled with Mass Spectrometry oleh Ángela Marrugal, Irene Ferrer, Maria Dolores Pastor, Laura Ojeda, Álvaro Quintanal-Villalonga, Amancio Carnero, Sonia Molina-Pinelo, Luis Paz-Ares

    Diterbitkan 2019-07-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  10. 10
    Tryptophan Modulation in Cancer-Associated Cachexia Mouse Models

    Tryptophan Modulation in Cancer-Associated Cachexia Mouse Models oleh M. Teresa Agulló-Ortuño, Esther Mancebo, Montserrat Grau, Juan Antonio Núñez Sobrino, Luis Paz-Ares, José A. López-Martín, Marta Flández

    Diterbitkan 2023-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  11. 11
    Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma

    Identification of Predictive Biomarkers of Response to HSP90 Inhibitors in Lung Adenocarcinoma oleh Ángela Marrugal, Irene Ferrer, David Gómez-Sánchez, Álvaro Quintanal-Villalonga, María Dolores Pastor, Laura Ojeda, Luis Paz-Ares, Sonia Molina-Pinelo

    Diterbitkan 2021-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  12. 12
    Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy

    Inhibition of HSP90 in Driver Oncogene-Defined Lung Adenocarcinoma Cell Lines: Key Proteins Underpinning Therapeutic Efficacy oleh Ángela Marrugal, Irene Ferrer, Álvaro Quintanal-Villalonga, Laura Ojeda, María Dolores Pastor, Ricardo García-Luján, Amancio Carnero, Luis Paz-Ares, Sonia Molina-Pinelo

    Diterbitkan 2023-09-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  13. 13
    462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data

    462 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 24 month survival data oleh Magnus Jaderberg, Victor Levitsky, Luis Paz-Ares, Lukasz Kuryk, Nicolas Isambert, Susana Cedres, Charles Ricordel, Santiago Ponce Aix, Anne-Sophie Moller, Sylvia Vetrhus

    Diterbitkan 2021-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  14. 14
    MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma

    MAP17 predicts sensitivity to platinum-based therapy, EGFR inhibitors and the proteasome inhibitor bortezomib in lung adenocarcinoma oleh Irene Ferrer, Álvaro Quintanal-Villalonga, Sonia Molina-Pinelo, Jose Manuel Garcia-Heredia, Marco Perez, Rocío Suárez, Santiago Ponce-Aix, Luis Paz-Ares, Amancio Carnero

    Diterbitkan 2018-08-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  15. 15
    361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers and clinical outcomes

    361 A randomised open-label phase I/II study adding ONCOS-102 to pemetrexed/cisplatin in patients with unresectable malignant pleural mesothelioma – 12 month analysis of biomarkers... oleh Magnus Jaderberg, Victor Levitsky, Luis Paz-Ares, Lukasz Kuryk, Nicolas Isambert, Susana Cedres, Xavier Serres, Charles Ricordel, Santiago Ponce Aix, Anne-Sophie Moller, Sylvia Vetrhus

    Diterbitkan 2020-11-01
    Artikel
    Simpan ke Daftar
    Disimpan di:
  16. 16
    A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry.

    A comparison of EGFR mutation testing methods in lung carcinoma: direct sequencing, real-time PCR and immunohistochemistry. oleh Bárbara Angulo, Esther Conde, Ana Suárez-Gauthier, Carlos Plaza, Rebeca Martínez, Pilar Redondo, Elisa Izquierdo, Belén Rubio-Viqueira, Luis Paz-Ares, Manuel Hidalgo, Fernando López-Ríos

    Diterbitkan 2012-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  17. 17
    Phase II Randomized Study of Plitidepsin (Aplidin), Alone or in Association with L-carnitine, in Patients with Unresectable Advanced Renal Cell Carcinoma

    Phase II Randomized Study of Plitidepsin (Aplidin), Alone or in Association with L-carnitine, in Patients with Unresectable Advanced Renal Cell Carcinoma oleh Patrick Schöffski, Vincente Guillem, Margarita Garcia, Fernando Rivera, Josep Tabernero, Martin Cullell, Jose Antonio Lopez-Martin, Patricia Pollard, Herlinde Dumez, Xavier Garcia del Muro, Luis Paz-Ares

    Diterbitkan 2009-03-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  18. 18
    Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer

    Emerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer oleh Charles M. Rudin, Martin Reck, Melissa L. Johnson, Fiona Blackhall, Christine L. Hann, James Chih-Hsin Yang, Julie M. Bailis, Gwyn Bebb, Amanda Goldrick, John Umejiego, Luis Paz-Ares

    Diterbitkan 2023-06-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  19. 19
    Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study

    Abemaciclib in combination with pembrolizumab for HR+, HER2− metastatic breast cancer: Phase 1b study oleh Hope S. Rugo, Peter Kabos, J. Thad Beck, Guy Jerusalem, Hans Wildiers, Elena Sevillano, Luis Paz-Ares, Michael J. Chisamore, Sonya C. Chapman, Anwar M. Hossain, Yanyun Chen, Sara M. Tolaney

    Diterbitkan 2022-11-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:
  20. 20
    A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms.

    A phase 2 study of an oral mTORC1/mTORC2 kinase inhibitor (CC-223) for non-pancreatic neuroendocrine tumors with or without carcinoid symptoms. oleh Edward Wolin, Alain Mita, Amit Mahipal, Tim Meyer, Johanna Bendell, John Nemunaitis, Pam N Munster, Luis Paz-Ares, Ellen H Filvaroff, Shaoyi Li, Kristen Hege, Hans de Haan, Monica Mita

    Diterbitkan 2019-01-01
    Dapatkan teks lengkap
    Artikel
    Simpan ke Daftar
    Disimpan di:

Alat Pencarian: